



2012, Vol. 19, No. 2, pp. 153–158
10.5603/CJ.2012.0027
Copyright © 2012 Via Medica
ISSN 1897–5593
Address for correspondence: Geetha Bhat, PhD, MD, Medical Director, Center for Heart Transplant and
Assist Devices, Advocate Christ Medical Center, Oak Lawn, IL, USA, tel: 708 684 7031, fax: 708 684 7040,
e-mail: geetha.bhat@advocatehealth.com
Received: 08.09.2011 Accepted: 01.12.2011
How effective are continuous flow left ventricular
assist devices in lowering high pulmonary artery
pressures in heart transplant candidates?
Sunil Pauwaa1, Geetha Bhat1, Antone J. Tatooles2, Ashim Aggarwal1,
Michele Martin1, Anup Kumar1, Harshit Modi1, Pat S. Pappas2
1Center for Heart Transplant and Assist Devices, Advocate Christ Medical Center, Oak Lawn, Illinois, USA
2Division of Cardiothoracic Surgery, Advocate Christ Medical Center, Oak Lawn, Illinois, USA
Abstract
Background: Pulmonary hypertension (PH) is considered a risk factor for morbidity and
mortality in patients undergoing heart transplantation. Medical therapy with oral and
pharmacologic agents is not always effective in reducing pulmonary artery (PA) pressures. Left
ventricular assist devices (LVADs) have been used to reduce PA pressures in cases of PH
unresponsive to medical therapy.
Methods and results: Our study sought to evaluate the effectiveness of axial- and centrifu-
gal-continuous flow LVADs in reversing PH in heart transplant candidates. Hemodynamics
were assessed pre- and post-operatively in nine patients undergoing HeartMate II and six
patients undergoing HeartWare continuous flow LVADs. Mean PA pressures were reduced
from 31.9 ± 10.6 mm Hg to 22.1 ± 6.6 mm Hg (p = 0.001), and pulmonary vascular resistance
was reduced from 3.08 ± 1.6 mm Hg to 1.8 ± 1.0 mm Hg (p = 0.007). This improvement was
seen within seven days of LVAD implantation. Three of 15 patients were successfully trans-
planted, with 100% survival at an average of 199 days post-transplant.
Conclusions: The results of this study suggest that both axial- and centrifugal-continuous
flow LVADs are effective in immediately lowering PA pressures in heart transplant candidates
with PH. (Cardiol J 2012; 19, 2: 153–158)
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Introduction
Pulmonary hypertension (PH) is common in
chronic heart failure (HF) and is an established risk
factor for morbidity and mortality in heart transplant
patients [1, 2]. PH is defined as a mean pulmonary
artery (PA) pressure > 25 mm Hg, systolic PA pres-
sure ≥ 50 mm Hg, pulmonary vascular resistance
(PVR) ≥ 2.5 Wood Units (WU) and (or) a transpul-
monary gradient (TPG) > 12 mm Hg [3, 4]. PH not
only increases early mortality after heart transplant,
but also at one year after transplant, with up to
a seven-fold increase in mortality with a TPG >
> 12 mm Hg [5, 6]. PH also increases right HF and
adverse events after heart transplantation [7].
Medical therapy with intravenous pulmonary va-
sodilators and inotropes superimposed on maximal
oral pharmacologic treatment has previously been
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used acutely to decrease PVR and PA pressures in
HF patients and heart transplant candidates [2, 8–11].
Fibrosis and remodeling, including smooth muscle
hypertrophy, may occur in the pulmonary vascula-
ture of chronic HF patients [12–14].  This remode-
ling can result in PH that is refractory to medical
therapy and which poses a high risk post-transplan-
tation.
Several studies have shown that left ventricu-
lar assist devices (LVADs) can be used to reduce
elevated PVR in HF patients, even when PH is re-
fractory to maximal medical therapy [15–18]. Most
studies have described the use of pulsatile LVADs
in reversing PH. More recently, a limited number
of studies have shown that continuous flow LVADs
can also reverse PH (Table 1). These studies have
used primarily axial-flow LVADs [16–19]. The goal
of our study was to evaluate the efficacy of continu-
ous-flow LVAD devices (both axial and centrifugal)
in lowering PA pressures in heart transplant can-
didates with PH.
Methods
This was a retrospective study of 15 patients
with advanced HF, a mean age of 51 years and a mean
left vetricular ejection fraction of 14.9% (Table 2) un-
dergoing continuous flow LVAD implantation as
bridge to transplantation (BTT). Nine (60%) of these
patients received HeartMate II (Thoratec Corp.)
axial-flow LVADs (approved by the Food and Drug
Administration [FDA] for BTT and destination thera-
py [DT]), and six (40%) patients received HeartWare
(HeartWare International Inc.) centrifugal-flow
LVADs (currently in clinical trials for BTT and DT).
Hemodynamics, including central venous pressure
(CVP), pulmonary artery systolic pressure (PAS),
pulmonary artery diastolic pressure (PAD), mean
Table 1. Effect of pulsatile and continuous flow LVADs on pulmonary hypertension.
Author (Reference #) Year # Patients Devices (number)        PVR [Wood Units]      MPAP [mm Hg]
Before After Before After
Pulsatile
Gallagher et al. [30] 1991 16 Novacor 3.8 1.5 NA NA
Smedira et al. [31] 1996 47 HeartMate XVE 5.0 3.7 NA NA
Adamson et al. [28] 1997 1 HeartMate XVE 6.6 2.8 43 19
Bhat et al. [33] 2003 1 HeartMate XVE 5.79 4.54 49 31
Al-Khaldi et al. [29] 2004 1 Novacor 7.1 1.2 NA NA




Pulsatile and continuous flow
Martin et al. [35] 2004 6 HeartMate XVE (4) 5.7 2.0 46 21
Novacor (1)
Jarvik 2000 (1)
Zimpfer et al. [17] 2007 35 Novacor (8) 5.1 2.0 44 18.4
Micromed Debakey (24)
Duraheart (3)
Haft et al. [36] 2007 34 HeartMate XVE (16) NA NA 37 20
HeartMate II (18)
Torre-Amione et al. [16] 2010 9 Micromed Debakey (7) 4.4 2.4 39 31
Thoratec PVAD (1)
Novacor (1)




Salzberg et al. [19] 2005 6 Micromed Debakey (17) 5 2.1 NA NA
Etz et al. [18] 2007 10 Incor (9) 4.8 2.2 42 24
Micromed Debakey (1)
LVADs — left ventricular assist devices; PVR — peripheral vascular resistance; MPAP — mean pulmonary artery pressures; NA — not applicable
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pulmonary artery pressure (MPAP), pulmonary
capillary wedge pressure (PCWP), cardiac output
(CO), cardiac index (CI), and mixed venous oxygen
saturation (SVO2), were assessed by right heart
catheterization within seven days of implantation
(mean five days) pre- and post-operatively. Right
heart catheterization and hemodynamics were ob-
tained by standard techniques [20]. All the patients
(15/15) were on continuous intravenous inotropic
therapy prior to LVAD implantation on milrinone
(average dose 0.49 mg/kg/min), and 60% (9/15) of
them were on dobutamine (average dose 4.67 mg/
/kg/min). Two patients were also on continuous in-
travenous nitroglycerine at an average dose of
30 mg/min. Sixty-six per cent (10/15) of patients
were maintained on oral sildenafil (average dose
74 mg/day) on discharge after LVAD implantation.
All patients were otherwise considered candidates
for transplantation and therefore implanted as BTT.
Pre- and post-operative hemodynamic values were
compared using SPSS v. 11.5 statistical software.
A p value of < 0.05 was considered significant.
Results
Pre- and post-operative hemodynamics of the
entire cohort (Table 3) and based on device type
(Table 4) were tabulated. There was significant
Table 2. Study population.
Patient Age (years) Gender Ethnicity Etiology LVEF (%) VAD Type
1* 26 F AA NICM 10 HW Centrifugal
2 42 M AA NICM 12 HW Centrifugal
3 58 M C ISCM 20 HW Centrifugal
4 55 M C NICM 10 HW Centrifugal
5 63 F C ISCM 20 HW Centrifugal
6 59 M C ISCM 17 HW Centrifugal
7 66 F AA NICM 10 HMII Axial
8 57 M AA NICM 15 HMII Axial
9* 43 M H NICM 18 HMII Axial
10* 55 F C ISCM 15 HMII Axial
11 26 M C ISCM 20 HMII Axial
12 34 M AA NICM 20 HMII Axial
13 62 M C ISCM 15 HMII Axial
14 60 M AA NICM 9 HMII Axial
15 61 M C ISCM 13 HMII Axial
*Transplanted; AA — African-American; C — Caucasian; HMII — HeartMate II; HW — HeartWare; ISCM — ischemic cardiomyopathy; LVEF — left
ventricular ejection fraction; NICM — non-ischemic cardiomyopathy; VAD — ventricular assist device
Table 3. Pre- and post-operative hemodynamics on right heart catheterization.
Hemodynamics Pre-VAD Post-VAD P
CVP [mm Hg] 11.6 ± 6.3 10.6 ± 6.3 0.33
PAS [mm Hg] 46.1 ± 15.3 30.4 ± 10.6 < 0.001
PAD [mm Hg] 22.9 ± 8.5 15.1 ± 5.8 0.006
MPAP [mm Hg] 31.9 ± 10.6 22.1 ± 6.6 0.001
PCWP [mm Hg] 20.4 ± 8.5 11.4 ± 4.9 0.01
PVR [Wood Units] 3.08 ± 1.6 1.8 ± 1.0 0.007
CO [L/min] 4.2 ± 1.2 5.7 ± 1.1 0.003
CI [L/min/m2] 2.0 ± 0.6 2.8 ± 0.5 0.001
SVO2 [%] 57.0 ± 12.3 68.8 ± 8.2 0.03
CI — cardiac index; CO — cardiac output; CVP — central venous pressure; PAD — pulmonary artery diastolic pressure; MPAP — mean pulmonary
artery pressure; PAS — pulmonary artery systolic pressure; PCWP — pulmonary capillary wedge pressure; PVR — peripheral vascular resistance;
SVO2 — mixed venous oxygen saturation
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improvement in PAS, PAD, MPAP, PVR, TPG, CO,
CI, and SVO2 after LVAD implantation. This im-
provement was seen within seven days of implan-
tation. Among these patients, the peak PVR was
6.9 WU (Patient #1, Table 2), and the peak MPAP
was 52 mm Hg (Patient #6, Table 2). None of the
patients required a right ventricular (RV) assist de-
vice after LVAD implantation.
Repeat right heart catheterization on 8/15
(53%) patients at an average of 423 days post-im-
plantation demonstrated MPAP of 20.3 ± 7.3 mm Hg,
and PVR of 1.7 ± 2.1 WU, indicating sustained
improvements in PA pressures and PVR.
Three of 15 (20%) patients were successfully
transplanted, with 100% survival at an average of
199 days post-transplant. Hemodynamics assessed
at an average of 73 days after transplant (average
471 days after LVAD implantation) demonstrated
mean MPAP of 18 ± 7 mm Hg with a mean PVR of
2.0 ± 1 WU.
Discussion
PH is a common consequence of congestive
HF, with an incidence as high as 60–80% in patients
with long-standing HF [21, 22]. In HF secondary to
left ventricular (LV) dysfunction, PH acutely aris-
es secondary to increased filling pressures within
the LV chamber. These increased pressures are
then transmitted to the left atrium and ultimately
result in an elevated PCWP and PH. Over time,
chronic HF results in pulmonary vascular remo-
deling and fibrosis with superimposed smooth mus-
cle hypertrophy [12–14].
PH ultimately leads to increased morbidity and
mortality in patients with chronic congestive HF
[23, 24]. Likewise, PH increases the risk of RV fail-
ure and complications post-heart transplant [2, 7].
PH can be treated medically using nitrates, hydrala-
zine, phosphodiesterase (PDE-5) inhibitors such as
sildenafil, and endothelin antagonists such as bosen-
tan [8, 10, 11]. In cases of PH refractory to oral
pharmacologic therapy, IV vasodilators such as mil-
rinone, prostaglandins and nitrates can be added to
test vaso-reactivity and ultimately lower PA pres-
sures [9, 11]. In some patients however, both oral
and IV vasodilator therapy may fail to lower PA
pressures, resulting in what has been termed ‘fixed’
or ‘irreversible’ PH.
LVADs have now come to be an accepted form
of treatment for advanced HF secondary to LV dys-
function, both as BTT and as permanent long-term
support otherwise known as DT [25–27]. LVADs
improve HF symptoms by unloading the LV and im-
proving circulation to the body and perfusion to the
end-organs. By volume unloading the LV, LVADs
decrease LV filling pressures, and thereby improve
congestion. This subsequently leads to decreased
left atrial or PCWP and decreases congestion with-
in the pulmonary vasculature. This is one of the
mechanisms by which LVADs are thought to im-
prove PA pressures.
Early case reports with LVADs and PH report-
ed the successful lowering of medically unrespon-
sive PH with pulsatile devices such as the Heart-
Mate XVE (Thoratec Corp.) [28] and Novacor
LVAD (WorldHeart Corp.) [29]. Likewise, a retro-
spective series by Gallagher et al. [30] demonstrat-
ed a reduction in the total pulmonary resistance
among 16 patients undergoing implantation with the
pulsatile Novacor LVAD. Smedira et al. [31] also
demonstrated that the HeartMate pulsatile device
could be used in patients with PH to successfully
lower PA pressures and TPG, with similar out-
Table 4. Comparison of hemodynamics based on device type.
Hemodynamics Axial pump (n = 9) Centrifugal pump (n = 6) P
Pre VAD Post VAD Pre VAD Post VAD
CVP [mm Hg] 12.2 ± 7.9 12.0 ± 4.2 10.1 ± 3.7 7.3 ± 5.2 0.94
PAS [mm Hg] 48.3 ± 9.7 39.7 ± 11.5 46.5 ± 10.1 31.8 ± 7.1 0.68
PAD [mm Hg] 23.7 ± 3.5 20.0 ± 4.1 23.3 ± 8.1 18.8 ± 5.2 0.08
MPAP [mm Hg] 33.0 ± 3.4 27.6 ± 7.4 32.1 ± 15.4 24.0 ± 10.6 0.31
PCWP [mm Hg] 20.2 ± 4.2 12.5 ± 3.5 17.2 ± 12.7 9.0 ± 10.4 0.94
PVR [Wood Units] 3.3 ± 3.6 2.4 ± 2.9 3.6 ± 0.8 1.7 ± 1.1 0.27
CO [L/min] 4.0 ± 0.6 6.09 ± 1.0 4.8 ± 2.5 5.8 ± 1.7 0.62
CI [L/min/m2] 2.0 ± 0.2 3.0 ± 0.6 2.4 ± 1.3 2.8 ± 0.3 0.55
SVO2 [%] 57.6 ± 4.4 72.0 ± 7.6 56.5 ± 11.5 71.0 ± 12.7 0.88
Abbreviations as in Table 3
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comes to patients without PH. The results of these
early studies have been confirmed in follow-up case
reports [32, 33] and a single recent large scale study
by Nair et al. [15].
With the advent of continuous flow devices,
studies utilizing both pulsatile and continuous flow
LVADs have shown that these devices can reverse
PH in patients with chronic HF [16–19, 34–36].
These studies have shown reversibility in patients
previously thought to have ‘irreversible’ or ‘fixed’
PH. Two studies have utilized exclusively continu-
ous flow devices in their series [18, 19]; however,
these studies have all used axial-flow LVADs.
Our single center experience expands on the
previous series of pulsatile and continuous axial-
flow LVADs reversing PH in chronic HF. Our study
suggests that both centrifugal and axial flow LVADs
can reverse PH early after implantation in chronic
advanced HF with a successful transplant outcome.
This improvement in PA pressures, occurring with-
in seven days of implantation, suggests that rever-
sal of PH can occur immediately, allowing for deci-
sions to be made regarding transplant candidacy.
Furthermore, this improvement in PH was main-
tained at an average of 423 days after LVAD implan-
tation, suggesting a sustained hemodynamic bene-
fit long after surgery. PA pressures remained within
normal limits even after heart transplant, suggest-
ing that the improvement in PH continues even
after transplantation and removal of the LVAD.
It should also be noted that despite significantly
elevated pre-LVAD PA pressures, none of the pa-
tients in this study required RVADs after LVAD
implantation. This is in contrast to previous stud-
ies that have demonstrated RVAD implantation in
as many as 37% of patients after LVAD [37].
Our study was limited by the small number of
patients involved and the fact that it was a retro-
spective review. The present study was not intend-
ed to compare the two devices (HeartWare and
HeartMate II), but rather to describe their overall
effect on PH in heart transplant candidates.
The two devices were able to significantly im-
prove hemodynamics in chronic HF patients; how-
ever, further studies with more patients will be
necessary to elucidate the mechanisms involved in
this process.
Conflict of interest: none declared
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